Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5087170
Max Phase: Preclinical
Molecular Formula: C16H18N2O5
Molecular Weight: 318.33
Molecule Type: Unknown
Associated Items:
ID: ALA5087170
Max Phase: Preclinical
Molecular Formula: C16H18N2O5
Molecular Weight: 318.33
Molecule Type: Unknown
Associated Items:
Canonical SMILES: COCc1ccccc1-c1ccc(C(=O)NC[C@@H](N)C(=O)O)o1
Standard InChI: InChI=1S/C16H18N2O5/c1-22-9-10-4-2-3-5-11(10)13-6-7-14(23-13)15(19)18-8-12(17)16(20)21/h2-7,12H,8-9,17H2,1H3,(H,18,19)(H,20,21)/t12-/m1/s1
Standard InChI Key: STBHODUQHYWLGQ-GFCCVEGCSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 318.33 | Molecular Weight (Monoisotopic): 318.1216 | AlogP: 1.23 | #Rotatable Bonds: 7 |
Polar Surface Area: 114.79 | Molecular Species: ZWITTERION | HBA: 5 | HBD: 3 |
#RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 2.11 | CX Basic pKa: 8.50 | CX LogP: -1.82 | CX LogD: -1.85 |
Aromatic Rings: 2 | Heavy Atoms: 23 | QED Weighted: 0.71 | Np Likeness Score: -0.49 |
1. Zhao F, Atxabal U, Mariottini S, Yi F, Lotti JS, Rouzbeh N, Liu N, Bunch L, Hansen KB, Clausen RP.. (2022) Derivatives of (R)-3-(5-Furanyl)carboxamido-2-aminopropanoic Acid as Potent NMDA Receptor Glycine Site Agonists with GluN2 Subunit-Specific Activity., 65 (1.0): [PMID:34918931] [10.1021/acs.jmedchem.1c01810] |
Source(1):